Fast and furious: What will the fast tracking of approvals for key drugs mean for China's pharma market?

China has long been a magnet for pharmaceutical multinationals looking to offset flattening growth in established markets

It offers rapid economic development, a population of around 1.4 billion with limited access to cutting-edge medicine, and changing lifestyles that have raised health expectations. Expanded access to state-funded healthcare, population aging and a growing burden of chronic disease are creating new opportunities for innovative drugs alongside low-cost generics. 

read more »